Ardelyx, Inc. (ARDX)
| Market Cap | 1.47B |
| Revenue (ttm) | 407.32M |
| Net Income (ttm) | -61.60M |
| Shares Out | 245.25M |
| EPS (ttm) | -0.26 |
| PE Ratio | n/a |
| Forward PE | 537.80 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,043,731 |
| Open | 6.04 |
| Previous Close | 5.99 |
| Day's Range | 5.97 - 6.09 |
| 52-Week Range | 3.21 - 8.40 |
| Beta | 0.66 |
| Analysts | Strong Buy |
| Price Target | 15.14 (+153.39%) |
| Earnings Date | Apr 30, 2026 |
About ARDX
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 an... [Read more]
Financial Performance
In 2025, Ardelyx's revenue was $407.32 million, an increase of 22.09% compared to the previous year's $333.62 million. Losses were -$61.60 million, 57.4% more than in 2024.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for ARDX stock is "Strong Buy." The 12-month stock price target is $15.14, which is an increase of 153.39% from the latest price.
News
Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF's Spring Clinical Meetings
Presentation evaluates the long-term impact of XPHOZAH® on serum electrolytes and select nutrition biomarkers Presentation evaluates the long-term impact of XPHOZAH® on serum electrolytes and select n...
Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026
WALTHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines t...
Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer
WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet signific...
Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026
WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX) (“Ardelyx” or the “Company”), a commercial-stage biopharmaceutical company focused on the development and commercializat...
Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx
WALTHAM, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet signific...
Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award
WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines t...
Ardelyx Transcript: Leerink Global Healthcare Conference 2026
IBSRELA is on track for $1 billion in sales by 2029, driven by strong growth, expanded sales force, and new indications like CIC. XPHOZAH's Non-Medicare segment is growing, and robust IP protection supports long-term value. Cash generation enables self-funded pipeline and commercial investments.
Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C
Post hoc analysis supports a reduction of time to first bowel movement and a consistent improvement in abdominal symptoms, including pain, discomfort, and bloating, during 12 weeks of treatment Post h...
Ardelyx to Participate in Upcoming Investor Conferences
WALTHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet signific...
Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions
DAYTONA BEACH, Fla. and WALTHAM, Mass.
Ardelyx Lead Drug Growth Fails To Lift Sentiment, Stock Drops
Ardelyx Inc. (NASDAQ: ARDX) shares are down during Friday's premarket session following a recent financial update for the fourth quarter of 2025.
Ardelyx Earnings Call Transcript: Q4 2025
Delivered 22% revenue growth in 2025, driven by IBSRELA's 73% increase and XPHOZAH's resilience despite Medicare changes. 2026 guidance projects strong double-digit growth, with robust cash reserves and pipeline expansion supporting long-term targets.
Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
IBSRELA revenue grew 73% in 2025 to $274.2 million and total revenues reached $407.3 million Patient-first XPHOZAH strategy preserved access and drove growth in total dispenses Development programs fo...
Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026
WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med...
Ardelyx Receives New Patent for Tenapanor
WALTHAM, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med...
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
WALTHAM, Mass., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med...
Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook
Company achieved significant commercial progress in 2025, generating approximately $378 million in product revenue 1
Ardelyx Transcript: Jefferies London Healthcare Conference 2025
The company highlighted strong growth in its IBSRELA and XPHOZAH franchises, driven by expanded sales efforts and high patient satisfaction. Guidance points to significant revenue potential, with profitability targeted for 2026 and a robust pipeline advancing.
Ardelyx Transcript: Wedbush Rewind ASN 2025 Conference
Conference discussions highlighted XPHOZAH's real-world effectiveness, manageable side effects, and strong physician interest. Market access remains dynamic due to regulatory changes, while pipeline expansion and organizational improvements support future growth.
Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week
WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med...
Ardelyx to Participate at the Jefferies Global Healthcare Conference in London
WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med...
Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference
WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med...
Ardelyx Earnings Call Transcript: Q3 2025
Q3 saw double-digit revenue growth, record results for IBSRELA, and solid gains for XPHOZAH. Full-year guidance was raised, a new pipeline asset was announced, and the company ended with a strong cash position, supporting future investments.
Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Q3 2025 product revenue of $105.5 million reflects 15% year-over-year growth IBSRELA ® Q3 revenue of $78.2 million reflects 92% year-over-year growth; IBSRELA guidance raised, 2025 revenue expected to...
Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology's 2025 Annual Meeting
IBSRELA patients reported treatment satisfaction in real-world survey Post-hoc analysis of T3MPO-1 and T3MPO-2 studies demonstrates effectiveness of IBSRELA in reducing abdominal bloating for patients...